SWOG clinical trial number
SWOG-8221 (INT-0007)

Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone

Closed
Phase
Accrual
81%
Published
Abbreviated Title
Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone
Activated
10/29/1982
Closed
11/15/1989

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1997

Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study.

JA Smith Jr;ED Crawford;JC Paradelo;B Blumenstein;BR Herschman;HB Grossman;DW Christie Journal of Urology 157:806-808

1993

Pre-operative irradiation plus radical cystectomy versus surgery alone for invasive bladder cancer: Final results of a randomized, prospective Southwest Oncology Group study.

JA Smith Jr;ED Crawford;BL Blumenstein;J Paradelo;BR Herschman American Urological Association Inc. 149:316A(#415)

1987

Preoperative radiation therapy in the treatment of bladdercancer.

ED Crawford;S Das;JA Smith, Jr Urol Clinics of North Am 14(4):781-787

1984

Southwest Oncology Group experience with randomized protocols for bladder cancer.

JA Smith Jr;ED Crawford In: Controlled Clinical Trials in Urologic Oncology . L Denis, GP Murphy, GR Prout Jr, F Schroder, eds. New York: Raven Press 249-254

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase